Loyola part of groundbreaking study that will test promising personalized medicine drugs for higher risk, rapidly growing cancers
MAYWOOD, Ill. -- Loyola University Medical Center is participating in an unprecedented nationwide effort to test promising new breast cancer drugs that are individually targeted to the characteristics of each patient's tumor.
This innovative clinical trial design for early stage breast cancer will enable researchers to quickly drop drugs that don't work, while designating effective drugs for further study.
Loyola is among 17 centers participating in the project, called I-SPY 2. "Personalized medicine is the new frontier in breast cancer treatment," said medical oncologist Dr. Kathy Albain, lead breast cancer specialist at the Loyola site. "This study will tell us, as rapidly as possible, which drugs work best on different types of tumors, and the drugs will be quickly selected on the basis of each woman's tumor characteristics. This could prove to be an enormous benefit to patients, especially women with the most aggressive cancers."
The five-year, $26 million project is led by the Foundation of the National Institutes of Health and is sponsored by the Biomarkers Consortium, a unique public-private partnership that includes the Food and Drug Administration, National Institutes of Health and major pharmaceutical companies.